← All indications
Hepatitis C, Chronic
INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS.
Drugs by status
Approved for this indication (20)
Phase 4 trials (35)
- efavirenz
- vitamin d3
- acetylcarnitine
- alfacalcidol
- maraviroc
- methoxy polyethylene glycol-epoetin beta
- etravirine
- tacrolimus
- acarbose
- tenofovir
- cyanocobalamin
- interferon alpha-2a
- amantadine
- nitazoxanide
- vitamin c
- beclabuvir
- pegylated-interferon
- hepatitis b vaccine (recombinant)
- sitagliptin
- cyclosporine
- buprenorphine
- emtricitabine
- hepatitis e vaccine
- losartan
- bictegravir
- methadone
- pioglitazone
- naloxone
- raltegravir
- tipranavir
- +5 more
Phase 3 trials (36)
- simvastatin
- alisporivir
- vitamin e
- berberine
- faldaprevir
- epoetin
- paroxetine
- danoprevir
- entecavir
- iodine
- irbesartan
- ursodeoxycholic acid
- narlaprevir
- peginterferon lambda-1a
- lactose
- ravidasvir
- immune globulin (human)
- mycophenolate
- Taribavirin
- tcm-700c
- pentoxifylline
- vaniprevir
- carvedilol
- coffee
- infliximab
- interferon alfacon-1
- silymarin
- viusid
- deleobuvir
- elvitegravir
- +6 more
Phase 2 trials (84)
- ezetimibe
- hymecromone
- mifepristone
- sovaprevir
- al-335
- setrobuvir
- azd7295
- bilb 1941 zw
- hemicellulose
- bms-824393
- mdl 28574
- Namodenoson
- chronvac-c
- fluvastatin
- cts-1027
- prednisone
- escitalopram
- gi 5005
- psi-352938
- gs-9256
- gsk2236805
- hydroxychloroquine
- aldesleukin
- rosuvastatin
- ic41
- icosapent ethyl
- Silipide
- emricasan
- idx184
- interferon alpha-5
- +54 more
Phase 1 trials (55)
Organizations
Organization Involved with Phase 4 Indications (153)
- Roche
- Schering-Plough
- ViiV Healthcare
- Pfizer
- Chugai
- FGK Clinical Research GmbH
- Getz Pharma
- Hannover Clinical Trial Center GmbH
- Indivior Inc.
- MinaPharm Pharmaceuticals
- PharmEvo Pvt Ltd
- Fundacion SEIMC-GESIDA
- German Liver Foundation
- Pacific Health Foundation
- National Institutes of Health (NIH)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Peter J. Ruane, M.D.
- University of Manitoba
- University of Pittsburgh
- Ain Shams University
- Baylor University
- Tzu Chi University
- Cairo University
- Cancer Research Network
- Center For Hepatitis C, Atlanta, GA
- University of London
- Harvard University
- Duke University
- Emory University
- Gottfried Wilhelm Leibniz Universität Hannover
- +123 more
Organization Involved with Phase 3 Indications (117)
- Human Genome Sciences
- Kadmon
- Serono
- Bausch Health Companies
- Debiopharm
- Merck Serono
- Sanofi
- Tibotec
- Romark
- Novartis
- Ascletis Pharmaceuticals Co., Ltd.
- Beijing Kawin Technology Share-Holding Co., Ltd.
- Biocad
- BioGeneric Pharma
- GlaxoSmithKline
- Institut Pasteur
- Leadiant Biosciences, Inc.
- Ortho Biotech, Inc.
- R-Pharm
- SciClone Pharmaceuticals
- Toray Industries, Inc
- Xiamen Amoytop Biotech Co., Ltd.
- Boehringer Ingelheim
- Pharco Pharmaceuticals
- Rottapharm
- TCM Biotech International Corp.
- Foundation for Liver Research
- Minnesota Veterans Medical Research and Education Foundation
- French National Agency for Research on AIDS and Viral Hepatitis
- National Cancer Institute (NCI)
- +87 more
Organization Involved with Phase 2 Indications (104)
- PPD
- ViroChem Pharma
- Achillion Pharmaceuticals
- Eisai
- Pharmasset
- Astellas
- Valneva
- Elan Pharmaceuticals
- Arrow Therapeutics
- Antipodean Pharmaceuticals, Inc.
- Anza Therapeutics, Inc.
- Avanti Polar Lipids, Inc.
- BioWest Therapeutics Inc
- Can-Fite BioPharma
- ChronTech Pharma AB
- Cocrystal Pharma, Inc.
- CureTech Ltd
- Digna Biotech S.L.
- GlobeImmune
- HanAll BioPharma Co., Ltd.
- Inovio Pharmaceuticals
- Ionis Pharmaceuticals, Inc.
- Kyowa Hakko Kirin
- Santaris Pharma A/S
- Sunshine Lake Pharma Co., Ltd.
- TaiwanJ Pharmaceuticals Co., Ltd
- Teva
- Trek Therapeutics, PBC
- ZymoGenetics
- Amarillo Biosciences, Inc.
- +74 more
Organization Involved with Phase 1 Indications (33)
- Sandoz
- Genentech
- GeneCure Biotechnologies
- Microbio Co Ltd
- Epoch Biosciences
- Avid Bioservices
- Scynexis, Inc.
- XTL Biopharmaceuticals
- Dynavax Technologies Corporation
- Pevion Biotech Ltd
- Transition Therapeutics
- Virobay Inc.
- National Heart, Lung, and Blood Institute (NHLBI)
- Temple University
- Institut National de la Santé Et de la Recherche Médicale, France
- Medical University of Warsaw
- University of Edinburgh
- University of Nebraska
- Covance
- GeneOne Life Science
- WCCT Global
- Spaulding Clinical Research Inc.
- Bio-Manguinhos
- Quest Clinical Research
- AIDS Research Consortium of Atlanta
- Allied Clinical Research
- Tower Cancer Research Foundation
- Orange Coast Medical Center
- Impact Clinical Trials
- Alamo Medical Research
- +3 more
Organization Involved with Other Experimental Indications (22)
- Parexel
- Yassin Abdelghaffar Charity Center for Liver Disease and Research
- Corporal Michael J. Crescenz VA Medical Center
- Aarhus University
- Medical University of Graz
- Federal University of Health Science of Porto Alegre
- Hillel Yaffe Medical Center
- Julius-Maximilians University
- Postgraduate Institute of Medical Education and Research
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
- University of Missouri, Kansas City
- Zagazig University
- Yassin Abdel Ghaffar Charity Center for Liver Disease and Research
- Bar Ilan University
- Ram Manohar Lohia Insitute of Medical Sciences
- Truman Medical Center
- Saint Luke's Health System
- The Swedish Research Council
- State Department of Health of Rio Grande do Sul
- The Geneva Foundation
- Reliant Pharmaceuticals
- Government of Punjab, India